

September 28, 2016

Dear Nuclear Medicine Professional,

Lantheus Medical Imaging, Inc. is committed to ensuring that the medical imaging community has reliable and secure access to TechneLite® (Technetium Tc 99m Generator) to meet the healthcare needs of patients. We believe we have the most globally <u>balanced</u> and <u>diversified</u> supply of molybdendum-99 (Mo-99), the parent isotope of technetium-99m, in the industry which provides us with reliable access and capacity to meet our customers' needs.

Over the past five years, we have aggressively undertaken several key initiatives to implement a balanced and diversified supply chain of Mo-99 for our TechneLite® generators. We have secured agreements with our supply partners worldwide to maximize access to this important medical isotope. In addition, we have taken an industry leadership position to provide Mo-99 sourced from Low-Enriched Uranium (LEU) and have successfully increased our LEU sourcing to deliver the greatest volume of LEU generators to the US market.

Our successful supply chain initiatives have prepared us for the National Research Universal (NRU) reactor's transition to emergency back-up supply of Mo-99 on October 31, 2016. Working closely with our suppliers ANSTO (Australia), IRE (Belgium) and NTP (South Africa) from whom we already receive the majority of our Mo-99 supply, we have planned our daily, weekly and monthly Mo-99 requirements. We also regularly meet to review near and long term supply needs in order to coordinate our balanced and diversified supply chain.

NTP is our leading LEU Mo-99 supplier and ANSTO and IRE both have initiatives underway to expand their facilities and production capacity. We are excited to report that ANSTO received approval and has recently implemented expanded weekly capacity to produce Mo-99 in their current facility. Additionally, ANSTO's new production facility project continues to make good progress with the goal of adding additional capacity to the supply chain in the second half of 2017. IRE received approval to increase its capacity by 50% and is currently the next in line to convert to an all LEU process, and this conversion is on track for completion in 2017.

As a leader in the field of diagnostic imaging for 60 years, we are steadfast in our commitment to meeting the needs of our customers and the patients they serve. We are confident that we will be able to provide secure and reliable supply of TechneLite® generators to the market now and in the future by leveraging our proven global Mo-99 supply chain.

As always, we thank you for your business and appreciate your support. We look forward to our continued partnership in meeting your nuclear medicine needs and the patients ultimately served by everything we collectively do.

Sincerely,

Mary Anne Heino

Maydonetters

President and Chief Executive Officer